Blocking the Enablers: Selective Inhibition of CDK9 Reins in an Unchecked Master Regulator
- PMID: 33607002
- DOI: 10.1016/j.chembiol.2021.01.022
Blocking the Enablers: Selective Inhibition of CDK9 Reins in an Unchecked Master Regulator
Abstract
In their quest to disable androgen receptor variants that drive castration-resistant prostate cancer, Richters et al. (2020) have hit upon a selective inhibitor of a transcriptional kinase that enables full-length mRNA synthesis. Drugging this essential kinase curbs tumor growth, thus making it an attractive focal target for transcription therapy.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Interests The author declares no competing interests.
Comment on
-
Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.Cell Chem Biol. 2021 Feb 18;28(2):134-147.e14. doi: 10.1016/j.chembiol.2020.10.001. Epub 2020 Oct 20. Cell Chem Biol. 2021. PMID: 33086052
Similar articles
-
Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.Cell Chem Biol. 2021 Feb 18;28(2):134-147.e14. doi: 10.1016/j.chembiol.2020.10.001. Epub 2020 Oct 20. Cell Chem Biol. 2021. PMID: 33086052
-
Phosphorylation of the androgen receptor at Ser81 is co-sustained by CDK1 and CDK9 and leads to AR-mediated transactivation in prostate cancer.Mol Oncol. 2021 Jul;15(7):1901-1920. doi: 10.1002/1878-0261.12968. Epub 2021 May 3. Mol Oncol. 2021. PMID: 33932081 Free PMC article.
-
Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.Prostate. 2022 Apr;82(5):505-516. doi: 10.1002/pros.24297. Epub 2022 Jan 17. Prostate. 2022. PMID: 35037287 Free PMC article.
-
Androgen receptors in hormone-dependent and castration-resistant prostate cancer.Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Pharmacol Ther. 2013. PMID: 23859952 Review.
-
Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.Int J Urol. 2016 Aug;23(8):654-65. doi: 10.1111/iju.13137. Epub 2016 Jun 14. Int J Urol. 2016. PMID: 27302572 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous